大环内酯类抗菌药物是治疗肺炎支原体肺炎的一线抗菌药物,对大环内酯类药物耐药是导致难治性肺炎支原体肺炎的主要原因之一。近年来,大环内酯类耐药现象快速增多,尤其在亚洲地区,给临床治疗肺炎支原体肺炎带来困难。有研究表明氟喹诺酮类和四环素类药物在缩短肺炎支原体肺炎症状持续时间方面显示出益处。然而,出于对这两种二线药物在儿童使用中的安全性考虑,临床医生在选择治疗方案时应该权衡风险和益处。本文将对氟喹诺酮和四环素治疗儿童大环内酯类耐药肺炎支原体肺炎的疗效及安全性等方面进行综述。
Macrolides are the first-line antibiotics for the treatment of Mycoplasma pneumoniae pneumonia. Resistance to macrolides is one of the main causes of refractory Mycoplasma pneumoniae pneumonia. In recent years, the resistance of macrolides has increased rapidly, especially in Asia, which produces great difficulties for clinical treatment. Fluoroquinolones and tetracyclines have shown benefits in shortening the duration of symptoms of Mycoplasma pneumoniae pneumonia. However, for the safety of second-line drugs in children, clinicians should balance the risks and benefits when choosing treatment options. This article will review the efficacy and safety of fluoroquinolone and tetracycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
Progresses of Fluoroquinolone and Tetracycline in the Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children
Min Tan1,2, Zhengxiu Luo1*
1Department of Respiratory Medicine, Children’s Hospital of Chongqing Medical University, Chongqing
2Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Key Laboratory of Pediatrics in Chongqing, Chongqing
Macrolides are the first-line antibiotics for the treatment of Mycoplasma pneumoniae pneumonia. Resistance to macrolides is one of the main causes of refractory Mycoplasma pneumoniae pneumonia. In recent years, the resistance of macrolides has increased rapidly, especially in Asia, which produces great difficulties for clinical treatment. Fluoroquinolones and tetracyclines have shown benefits in shortening the duration of symptoms of Mycoplasma pneumoniae pneumonia. However, for the safety of second-line drugs in children, clinicians should balance the risks and benefits when choosing treatment options. This article will review the efficacy and safety of fluoroquinolone and tetracycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
谭 敏,罗征秀. 氟喹诺酮和四环素治疗儿童耐大环内酯类肺炎支原体肺炎的研究进展Progresses of Fluoroquinolone and Tetracycline in the Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children[J]. 临床医学进展, 2022, 12(04): 3111-3116. https://doi.org/10.12677/ACM.2022.124449
参考文献ReferencesMcCulloh, R. and Patel, K. (2016) Recent Developments in Pediatric Community-Acquired Pneumonia. Current Infectious Disease Reports, 18, 14. <br>https://doi.org/10.1007/s11908-016-0521-1Choi, Y., Chung, E., Lee, E., et al. (2022) Mycoplasma pneumoniae Clinical Characteristics of Macrolide-Refractory Pneumonia in Korean Children: A Multicenter Retrospective Study. Journal of Clinical Medicine, 11, 306.
<br>https://doi.org/10.3390/jcm11020306Yin, Y.D., et al. (2017) Mycoplasma pneumoniae Macrolide-Resistant Prevalence and Clinical Aspects in Adult Patients with Community-Acquired Pneumonia in China: A Prospective Multicenter Surveillance Study. Journal of Thoracic Disease, 9, 3774-3781. <br>https://doi.org/10.21037/jtd.2017.09.75Lee, H., Choi, Y., Sohn, Y., et al. (2021) Mycoplasma pneumoniae Clinical Efficacy of Doxycycline for Treatment of Macrolide-Resistant Pneumonia in Children. Antibiotics (Basel, Switzerland), 10, 192.
<br>https://doi.org/10.3390/antibiotics10020192Guo, D.X., Hu, W.J., Wei, R., et al. (2019) Epidemiology and Mechanism of Drug Resistance of Mycoplasma pneumoniae in Beijing, China: A Multicenter Study. Bosnian Journal of Basic Medical Sciences, 19, 288-296.
<br>https://doi.org/10.17305/bjbms.2019.4053Qu, J., Chen, S., Bao, F., et al. (2019) Molecular Characterization and Analysis of Mycoplasma pneumoniae among Patients of All Ages with Community-Acquired Pneumonia during an Epidemic in China. International Journal of Infectious Diseases, 83, 26-31. <br>https://doi.org/10.1016/j.ijid.2019.03.028Wu, T., Wang, N., Liu, F., et al. (2021) Mycoplasma pneumoniae Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children with Infection. Open Forum Infectious Diseases, 8, ofab416.
<br>https://doi.org/10.1093/ofid/ofab416Kim, J.H., Kim, J.Y., Yoo, C.H., et al. (2017) Macrolide Resistance and Its Impacts on M. pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea. Allergy, Asthma & Immunology Research, 9, 340-346.
<br>https://doi.org/10.4168/aair.2017.9.4.340Oishi, T., Takahashi, K., Wakabayashi, S., et al. (2019) Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrobial Agents and Chemotherapy, 63, 1-6. <br>https://doi.org/10.1128/AAC.02517-18Razin, S., Yogev, D. and Naot, Y. (1998) Molecular Biology and Pathogenicity of Mycoplasmas. Microbiology and Molecular Biology Reviews: MMBR, 62, 1094-1156. <br>https://doi.org/10.1128/MMBR.62.4.1094-1156.1998Waites, K., Xiao, L., Liu, Y., et al. (2017) Mycoplasma pneumoniae from the Respiratory Tract and beyond. Clinical Microbiology Reviews, 30, 747-809. <br>https://doi.org/10.1128/CMR.00114-16李少丽, 孙红妹. 肺炎支原体大环内酯类抗生素全球耐药现状和耐药机制研究进展[J]. 中华微生物学和免疫学杂志, 2018, 38(5): 395-400.Li, S.L., Sun, H.M., Zhu, B.L., et al. (2017) Whole Genome Analysis Reveals New Insights into Macrolide Resistance in Mycoplasma pneumoniae. Biomedical and Environmental Sciences: BES, 30, 343-350.中华医学会儿科学分会临床检验学组. 儿童肺炎支原体呼吸道感染实验室诊断中国专家共识[J]. 中华检验医学杂志, 2019, 42(7): 507-513.Lucier, T.S., et al. (1995) Transition Mutations in the 23S rRNA of Erythromycin-Resistant Isolates of Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 39, 2770-2773. <br>https://doi.org/10.1128/AAC.39.12.2770Miranda, P.V.D.H., Tatay-Dualde, J., Christian, D.L.F., et al. (2017) Molecular Resistance Mechanisms of Mycoplasma agalactiae to Macrolides and Lincomycin. Veterinary Microbiology, 211, 135-140.
<br>https://doi.org/10.1016/j.vetmic.2017.10.012Cao, B., Qu, J.-X.,Yin, Y.-D., et al. (2017) Overview of Antimicrobial Options for Mycoplasma pneumoniae Pneumonia: Focus on Macrolide Resistance. The Clinical Respiratory Journal, 11, 419-429. <br>https://doi.org/10.1111/crj.12379Lu, C., Yen, T., Chang, L., et al. (2020) Multiple-Locus Variable-Number Tandem-Repeat Analysis (MLVA) of Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae in Children in Taiwan. Journal of the Formosan Medical Association, 119, 1539-1545. <br>https://doi.org/10.1016/j.jfma.2019.12.008Lee, H., Yun, K.W., Lee, H.J., et al. (2018) Antimicrobial Therapy of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children. Expert Review of Anti-Infective Therapy, 16, 23-34.
<br>https://doi.org/10.1080/14787210.2018.1414599Ahn, J., Cho, H., Li, D., et al. (2021) Efficacy of Tetracyclines and Fluoroquinolones for the Treatment of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis. BMC Infectious Diseases, 21, Article No. 1003. <br>https://doi.org/10.1186/s12879-021-06508-7Kawai, Y., Miyashita, N., Yamaguchi, T., et al. (2012) Clinical Efficacy of Macrolide Antibiotics against Genetically Determined Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Paediatric Patients. Respirology (Carlton, Vic), 17, 354-362. <br>https://doi.org/10.1111/j.1440-1843.2011.02102.xIshiguro, N., Koseki, N., Kaiho, M., et al. (2017) Therapeutic Efficacy of Azithromycin, Clarithromycin, Minocycline and Tosufloxacin against Macrolide-Resistant and Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia in Pediatric Patients. PLoS ONE, 12, e0173635. <br>https://doi.org/10.1371/journal.pone.0173635Principi, N. and Esposito, S. (2013) Macrolide-Resistant Mycoplasma pneumoniae: Its Role in Respiratory Infection. The Journal of Antimicrobial Chemotherapy, 68, 506-511. <br>https://doi.org/10.1093/jac/dks457Tsai, T., Tsai, C., Kuo, K., et al. (2021) Rational Stepwise Approach for Mycoplasma pneumoniae Pneumonia in Children. Journal of Microbiology, Immunology, and Infection, 54, 557-565. <br>https://doi.org/10.1016/j.jmii.2020.10.002Cardinale, F., Chironna, M., Chinellato, I., et al. (2013) Clinical Relevance of Mycoplasma pneumoniae Macrolide Resistance in Children. Journal of Clinical Microbiology, 51, 723-724. <br>https://doi.org/10.1128/JCM.02840-12Dai, F.F., Liu, F.Q., Chen, X., et al. (2021) The Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children. Journal of Clinical Pharmacy and Therapeutics, 46, 705-710. <br>https://doi.org/10.1111/jcpt.13331Kawai, Y., Miyashita, N., Kubo, M., et al. (2013) Therapeutic Efficacy of Macrolides, Minocycline, and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Pediatric Patients. Antimicrobial Agents and Chemotherapy, 57, 2252-2258. <br>https://doi.org/10.1128/AAC.00048-13Jackson, M. and Schutze, G. (2016) The Use of Systemic and Topical Fluoroquinolones. Pediatrics, 138, e20162706.
<br>https://doi.org/10.1542/peds.2016-2706Patel, K. and Goldman, J. (2016) Safety Concerns Surrounding Quinolone Use in Children. Journal of Clinical Pharmacology, 56, 1060-1075. <br>https://doi.org/10.1002/jcph.715Gough, A., Barsoum, N., Mitchell, L., McGuire, E., et al. (1979) Juvenile Canine Drug-Induced Arthropathy: Clinicopathological Studies on Articular Lesions Caused by Oxolinic and Pipemidic Acids. Toxicology and Applied Pharmacology, 51, 177-187. <br>https://doi.org/10.1016/0041-008X(79)90020-6Binz, J., Adler, C. and So, T. (2016) The Risk of Musculoskeletal Adverse Events with Fluoroquinolones in Children: What Is the Verdict Now? Clinical Pediatrics, 55, 107-110. <br>https://doi.org/10.1177/0009922815599959Kim, Y., Park, G., Kim, S., et al. (2021) Fluoroquinolone and No Risk of Achilles-Tendinopathy in Childhood Pneumonia under Eight Years of Age—A Nationwide Retrospective Cohort. Journal of Thoracic Disease, 13, 3399-3408.
<br>https://doi.org/10.21037/jtd-20-2256Bradley, J., Kauffman, R., Balis, D., et al. (2014) Assessment of Musculoskeletal Toxicity 5 Years after Therapy with Levofloxacin. Pediatrics, 134, e146-e153. <br>https://doi.org/10.1542/peds.2013-3636Chopra, I. and Roberts, M. (2001) Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiology and Molecular Biology Reviews: MMBR, 65, 232-260.
<br>https://doi.org/10.1128/MMBR.65.2.232-260.2001Okada, T., Morozumi, M., Tajima, T., et al. (2012) Rapid Effectiveness of Minocycline or Doxycycline against Macrolide-Resistant Mycoplasma pneumoniae Infection in a 2011 Outbreak among Japanese Children. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 55, 1642-1649.
<br>https://doi.org/10.1093/cid/cis784Grossman, E., Walchek, A. and Freedman, H. (1971) Tetracyclines and Permanent Teeth: The Relation between Dose and Tooth Color. Pediatrics, 47, 567-570. <br>https://doi.org/10.1542/peds.47.3.567Todd, S., Dahlgren, F., Traeger, M., et al. (2015) No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever. The Journal of Pediatrics, 166, 1246-1251.
<br>https://doi.org/10.1016/j.jpeds.2015.02.015Uehara, S., Sunakawa, K., Eguchi, H., et al. (2011) Japanese Guidelines for the Management of Respiratory Infectious Diseases in Children 2007 with Focus on Pneumonia. Pediatrics International: Official Journal of the Japan Pediatric Society, 53, 264-276. <br>https://doi.org/10.1111/j.1442-200X.2010.03316.xBébéar, C., Pereyre, S. and Peuchant, O. (2011) Mycoplasma pneumoniae: Susceptibility and Resistance to Antibiotics. Future Microbiology, 6, 423-431. <br>https://doi.org/10.2217/fmb.11.18